The vernakalant story: How did it come to approval in Europe and what is the delay in the U.S.A?

Current Cardiology Reviews

Volumn 10, Issue 4, 2014, Pages 309-314

  John Camm, A ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Amiodarone; Atrial fibrillation; Cardioversion; Vernakalant

Indexed keywords

VERNAKALANT;

ARTICLE; CARDIOVERSION; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; DRUG APPROVAL; EUROPE; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; HEART ELECTROPHYSIOLOGY; HUMAN; PHARMACEUTICAL CARE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; THERAPY DELAY; UNITED STATES;

ANISOLES; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CHEST PAIN; DRUG APPROVAL; DYSPNEA; ELECTRIC COUNTERSHOCK; EUROPE; HUMANS; PYRROLIDINES; TIME FACTORS; UNITED STATES;

EID: 84904757780     PISSN: 1573403X     EISSN: 18756557     Source Type: Journal    
DOI: 10.2174/1573403X10666140513103709     Document Type: Article

References (21)

1. Burashnikov A, Antzelevitch C. Role of Late Sodium Channel Current Block in the Management of Atrial Fibrillation. Cardiovasc Drugs Ther 2013; 27(1): 79-89.
2. EU Summary of Product Characteristics, BRINAVESS, MSD, 2010.
3. de Riva-Silva M, Montero-Cabezas JM, Salgado-Aranda R, LópezGil M, Fontenla-Cerezuela A, Arribas-Ynsaurriaga F. 1: 1 Atrial Flutter After Vernakalant Administration for Atrial Fibrillation Cardioversion. Rev Esp Cardiol 2012; 65(11): 1062-4.
4. Bash LD, Buono JL, Davies GM, et al. Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation. Cardiovasc Drugs Ther 2012; 26(2): 167-79.
5. Burashnikov A, Pourrier M, Gibson JK, Lynch JJ, Antzelevitch C. Rate-dependent effects of vernakalant in the isolated nonremodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol. Circ Arrhythm Electrophysiol 2012; 5(2): 400-8.
6. Camm AJ, Toft E, Torp-Pedersen C, et al. Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, doubleblind, placebo-controlled trial. Europace 2012; 14(6): 804-9.
7. Buccelletti F, Iacomini P, Botta G, et al. Efficacy and safety of vernakalant in recent-onset atrial fibrillation after the European medicines agency approval: systematic review and meta-analysis. J Clin Pharmacol 2012; 52(12): 1872-8.
8. Torp-Pedersen C, Camm AJ, Butterfield NN, Dickinson G, Beatch GN. Vernakalant: Conversion of atrial fibrillation in patients with ischemic heart disease. Int J Cardiol 2013; 166(1): 147-51.
9. Heldal M, Atar D. Pharmacological conversion of recent-onset atrial fibrillation: A systematic review. Scand Cardiovasc J 2013; 47(1): 2-10.
10. Farkowski MM, Maciag A, Dabrowski R, Pytkowski M, Kowalik I, Szwed H. Clinical efficacy of antazoline in rapid cardioversion of paroxysmal atrial fibrillation--a protocol of a single center, randomized, double-blind, placebo-controlled study (the AnPAF Study). Trials 2012; 13: 162.
11. Kline SR, Dreifus LS, Watanabe Y, McGarry TF, Likoff W. Evaluation of the antiarrhythmic properties of antazoline. A preliminary study. Am J Cardiol 1962; 9: 564-7.
12. Friederich P, Pfizenmayer H. The novel Kv1. 5 channel blocker vernakalant for successful treatment of new-onset atrial fibrillation in a critically ill abdominal surgical patient. Br J Anaesth 2011; 107(4): 644-5.
13. Torp-Pedersen C, Raev DH, Dickinson G, Butterfield NN, Mangal B, Beatch GN. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion. Circ Arrhythm Electrophysiol 2011; 4(5): 637-43.
14. Bechard J, Gibson JK, Killingsworth CR, et al. Vernakalant selectively prolongs atrial refractoriness with no effect on ventricular refractoriness or defibrillation threshold in pigs. J Cardiovasc Pharmacol 2011; 57(3): 302-7.
15. Camm AJ, Capucci A, Hohnloser SH, et al. A randomized activecontrolled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol 2011; 57(3): 313-21.
16. Pratt CM, Roy D, Torp-Pedersen C, et al. Atrial Arrhythmia Conversion Trial (ACT-III) Investigators. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. Am J Cardiol 2010; 106(9): 1277-83.
17. Stiell IG, Roos JS, Kavanagh KM, Dickinson G. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm. Am Heart J 2010; 159(6): 1095-101.
18. Kowey PR, Dorian P, Mitchell LB, et al. Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol 2009; 2(6): 652-9.
19. Roy D, Pratt CM, Torp-Pedersen C, et al. Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebocontrolled trial. Circulation 2008; 117(12): 1518-25.
20. Dorian P, Pinter A, Mangat I, Korley V, Cvitkovic SS, Beatch GN. The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans. J Cardiovasc Pharmacol 2007; 50(1): 35-40.
21. Roy D, Rowe BH, Stiell IG, et al. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol 2004; 44(12): 2355-61.